Conference
A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer
Authors
Ray-Coquard I; Haluska P; O'Reilly S; Cottu PH; Elit L; Provencher DM; Beckmann MW; Bosserman LD; Jacod S; Houe V
Volume
31
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Publication Date
May 20, 2013
Name of conference
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Conference place
Chicago, IL
Conference start date
May 31, 2013
Conference end date
June 4, 2013
Conference proceedings
JOURNAL OF CLINICAL ONCOLOGY
Issue
15
ISSN
0732-183X